HeartFlow is a medical technology company that revolutionizes cardiovascular disease diagnosis and treatment. The company offers the HeartFlow Analysis, a personalized and non-invasive cardiac test. This innovative technology equips physicians worldwide with critical information to make informed care decisions for patients suspected of having coronary artery disease, a leading cause of mortality globally. With a foundation in extensive scientific research and advancement, HeartFlow strives to establish a new standard of cardiovascular care. By prioritizing doctors' ease and patient safety, the company eliminates unnecessary risks and costs associated with invasive procedures. HeartFlow aims to save lives, enhance patient experiences, and reduce the overall cost of care.
Type | Valuation | Date | PPS | Source |
---|---|---|---|---|
409-A | ||||
409-A | ||||
409-A | ||||
3 more internal marks |
Yes. HeartFlow is a private venture-backed company. Investors usually purchase preferred stock and employees typically receive common stock options or restricted stock units (RSUs) as part of their compensation.
Since it is not publicly listed, there is no HeartFlow stock symbol or HeartFlow ticker symbol assigned for HeartFlow.
Private companies typically reserve a stock symbol up to two years prior to an IPO, and disclose this when they file a Form S-1 with the Security Exchange Commission when they start the IPO process.
If you own shares of a private company, it may be possible to find liquidity for your holdings before the company goes public. Finding the right private market broker can make all the difference as the best brokers can leverage deep industry relationships and negotiate on your behalf.
If you are interested in selling private stock you can reach out to Premier brokers for more information.
Private market transactions can be complex and may involve company approvals, legal purchase agreements and wires to third parties. Trades can take 30 - 60 days to complete which is why many investors work with experienced private market brokers to help guide the process.
Direct share transfers typically require issuer approvals. Issuers may exercise the right of first refusal (ROFR) in order to direct the seller to a buyer of their choosing.
Some issuers do not allow transactions. In these cases, buyers will need to purchase indirect interests in the business via special purpose vehicles (SPVs) or forward purchase contracts (forwards).
HeartFlow stock does not trade publicly on Nasdaq or NYSE because it is still a private company. HeartFlow stock might be available for purchase in the secondary markets, but HeartFlow stock is not available for purchase by the general public, and can not be purchased through traditional brokerage accounts.
Only accredited investors and qualified purchasers can buy private stock. These investors buy pre-IPO stock in the secondary market from existing employees and investors.
To learn more about the market for HeartFlow stock, talk to the best brokers on the planet.
Accredited investors can purchase shares in private companies like HeartFlow. Investors can rely on Notice Premier Brokers to find supply and guide them through the trading process.
Because HeartFlow is privately held, its stock is not available for purchase through public stock exchanges like the NYSE or Nasdaq. Retail investors can not access this stock via traditional brokerage accounts, and are not allowed to invest directly in HeartFlow pre-IPO.
Notice Price is algorithmically generated based on a number of inputs like private market activity, official company filings, internal marks, and comparables.
Developing accurate pricing for the private market, and making that pricing available to everyone has always been our mission.